Assetmark Inc. Acquires 9,612 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Assetmark Inc. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 10.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,771 shares of the biopharmaceutical company’s stock after purchasing an additional 9,612 shares during the period. Assetmark Inc. owned 0.08% of Halozyme Therapeutics worth $4,913,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC increased its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after purchasing an additional 200 shares during the period. Verdence Capital Advisors LLC grew its position in Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 252 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in Halozyme Therapeutics by 0.6% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock worth $2,279,000 after buying an additional 302 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its position in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 322 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on HALO shares. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Benchmark reissued a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Trading Up 1.4 %

Shares of HALO stock opened at $60.98 on Friday. The stock’s fifty day moving average price is $55.70 and its two-hundred day moving average price is $54.77. The company has a market cap of $7.51 billion, a PE ratio of 17.78, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock valued at $1,754,451 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.